FDA fast tracks Diamyd’s immunotherapy for managing type 1 diabetes

Swedish biotech Diamyd has won a fast track designation for its eponymous type 1 diabetes immunotherapy Diamyd (rhGAD65/alum) from the US Food and Drug Administration (FDA).